{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation was not calculated for 2 participants.","groupId":"OG000","spread":"NA","value":"13.3"},{"groupId":"OG001","spread":"10.7","value":"19.9"},{"groupId":"OG002","spread":"13.9","value":"18.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Alisertib 30 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG000","title":"Alisertib 30 mg ECT BID 7D"},{"description":"alisertib 40 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG001","title":"Alisertib 40 mg ECT BID 7D"},{"description":"Alisertib 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose).","id":"OG002","title":"Alisertib 50 mg ECT BID 7D"}],"paramType":"MEAN","populationDescription":"PK evaluable population included all participants for whom there were sufficient dosing and alisertib concentration time data to permit non-compartmental PK analysis. Here number of participants analyzed were participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 7 predose and at multiple timepoints (up to 12 hours) postdose","title":"Terminal Half-Life (t1/2) for Alisertib as Enteric Coated Tablet (ECT) With Twice Daily for 7 Days (BID7D) Dosing at Day 7","type":"PRIMARY","unitOfMeasure":"h"}